The stock of Revance Therapeutics Inc. (NASDAQ:RVNC) decreased by -$2.89 on Tuesday to finish at $13.81, down -17.31 percent. The last five days have seen an average of 4,233,360 shares of common stock traded. 13 times new highs were reached in the current year, with a fall of -$4.65. The average number of shares traded over the last 20 days was 2,040,435, while the average volume over the last 50 days totaled 1,690,002.
RVNC stock dropped -20.22% since last month. On 09/19/23, the company’s shares reached a one-month low of $11.10. The stock touched a high of $37.98 on 05/09/23, after rallying from a low of $15.13 in 52 weeks. The price of RVNC stock has declined by -25.19% or -$4.65 this year, reaching a new high 13 times. Still, the stock price is down -63.64% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
RVNC stock investors should be aware that Revance Therapeutics Inc. (RVNC) stock had its last reported insider trading activity 14 days ago on Sep 06. On Sep 06, SVP, GC & Secretary Moxie Dwight sold 11,000 shares at $17.06 each. This transaction resulted in the insider making $187,704. On Sep 05, Moxie Dwight sold 23,853 shares at a price of US$17.81. After the transaction, the insider now owns 55,066 shares. CEO Foley Mark J had earlier sold 26,279 shares on Aug 03 for $22.57 a share. The transaction was completed for $593,151.
Valuation Metrics
Beta for the stock is 0.80. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 6.69, the price-to-book (PB) ratio of 43.16.
Financial Health
For the three months ended June 29, Revance Therapeutics Inc.’s quick ratio was 4.70, while its current ratio was 5.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 14.19, and the total debt to equity ratio is 14.77. As far as profitability goes, gross margin for the trailing twelve months is 61.50% percent. Based on annual data, it had gross profit of $80.9 million and revenue of $132.56 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. RVNC’s return on assets (ROA) during the last 12 months has been -58.70%. There was a -87.30% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -903.30%.
Earnings Surprise
According to Revance Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $58.13 million, while revenues rose by 51.2% to $49.33 million. It was predicted that Revance Therapeutics Inc.’s quarterly earnings would be -$0.8, but it ended up being -$0.78, beating the consensus by -2.60%. EBITDA was -$62.9 million for the quarter. At the end of Revance Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 570.75 million, while its total debt was $432.39 million. Equity owned by shareholders amounts to $87.95 million.
Technical Picture
Here’s a quick look at Revance Therapeutics Inc.’s (RVNC) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 23.22%, suggesting the stock is oversold, with a 107.35% historical volatility rate.
The stochastic %K and %D were 42.30% and 46.47% respectively, while the average true range (ATR) was 1.41. Based on the 14-day stochastic reading of 37.43%, the RSI (14) reading is 26.28%. On the 9-day MACD Oscillator, the stock is at -0.36, and the 14-day reading is at -0.89.
Analyst Ratings
In its most recent analyst report, Exane BNP Paribas raised its rating on Revance Therapeutics Inc. (NASDAQ: RVNC) to a Neutral. Prior to this, analysts firm rated the stock as an Underperform. Analysts have assigned Revance Therapeutics Inc. (RVNC) an Buy rating. RVNC is a stock that is recommended for selling by 0 brokerage firms, while 2 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 1 rate it overweight and 9 others recommend it as a buy.
What is RVNC’s price target for the next 12 months?
The current consensus forecast for the stock is between $20.00 and $65.00, with a median target price of $40.00. In analyzing these forecasts, the average price target given by analysts for Revance Therapeutics Inc. (RVNC) is $39.33.
